Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
28 Décembre 2023 - 10:15PM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan
Mikkelsen, President & Chief Executive Officer, Scott Smith,
Executive Vice President & Chief Financial Officer, and Kennett
Sprogøe, Ph.D., Executive Vice President, Head of Research &
Product Development, will participate in the 42nd Annual J.P.
Morgan Healthcare Conference.
Details:
Event |
42nd Annual J.P. Morgan Healthcare Conference |
Location |
San Francisco, CA |
Date |
Monday, January 8, 2024 |
Time |
12:00-12:40 p.m. Eastern Time / 9:00-9:40 a.m. Pacific Time |
|
|
A live webcast of the event will be available via
the Investors & News section of the Ascendis
Pharma website at investors.ascendispharma.com. A webcast
replay will also be available on this website shortly after
conclusion of the event for 30 days.
About Ascendis Pharma A/SAscendis
Pharma is applying its innovative platform technology to build a
leading, fully integrated biopharma company focused on making a
meaningful difference in patients’ lives. Guided by its core values
of patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark and has additional
facilities in Germany (Heidelberg and Munich) and the United States
(Palo Alto and Redwood City, California, and Princeton, New
Jersey). Please visit ascendispharma.com to learn more.
Forward-Looking Statements This
press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release
regarding Ascendis’ future operations, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
(i) Ascendis’ ability to apply its TransCon platform to build a
leading, fully integrated, global biopharma company, and (ii)
Ascendis’ use of its TransCon technologies to create new and
potentially best-in-class therapies. Ascendis may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Ascendis makes, including
the following: dependence on third party manufacturers,
distributors and service providers for Ascendis’ products and
product candidates; unforeseen safety or efficacy results in
Ascendis’ development programs or on-market products; unforeseen
expenses related to commercialization of any approved Ascendis
products; unforeseen expenses related to Ascendis’ development
programs; unforeseen selling, general and administrative expenses,
other research and development expenses and Ascendis’ business
generally; delays in the development of its programs related to
manufacturing, regulatory requirements, speed of patient
recruitment or other unforeseen delays; Ascendis’ ability to obtain
additional funding, if needed, to support its business activities;
the impact of international economic, political, legal, compliance,
social and business factors, including inflation, the effects on
its business from the worldwide COVID-19 pandemic and ongoing
conflicts such as that in the region surrounding Ukraine and
Russia. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
Ascendis’ business in general, see Ascendis’ Annual Report on Form
20-F filed with the U.S. Securities and Exchange Commission (SEC)
on February 16, 2023 and Ascendis’ other future reports filed with,
or submitted to, the SEC. Forward-looking statements do not reflect
the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma
logo, the company logo and TransCon are trademarks owned by the
Ascendis Pharma group. © December 2023 Ascendis Pharma A/S.
Investor Contacts:Tim LeeAscendis Pharma+1 (650)
374-6343tle@ascendispharma.comir@ascendispharma.com |
Media Contact:Melinda BakerAscendis Pharma+1 (650)
709-8875media@ascendispharma.com |
Patti BankICR Westwicke+1 (415)
513-1284patti.bank@westwicke.com |
|
Ascendis Pharma AS (NASDAQ:ASND)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ascendis Pharma AS (NASDAQ:ASND)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024